Non-alcoholic steatohepatitis (NASH) is a chronic disease that causes extensive and potentially fatal liver fibrosis; it is a leading cause of liver transplant. Significant increases in rates of diabetes and obesity have made liver disease a major public health challenge in China, where the prevalence of NASH is the highest in the world. Owing to the high unmet need and lack of approved disease-modifying therapies (DMTs) for NASH, China offers substantial commercial opportunity for drug developers. Only off-label generic drugs are prescribed for NASH, but we anticipate the launch and gradual but substantial uptake of Galmed Pharmaceuticals’ Aramchol, Novo Nordisk’s semaglutide, and Sagimet Biosciences’ TVB-2640. These novel therapies will command premium pricing given the lack of other therapies and drive tremendous growth of China’s NASH market throughout the forecast period. Additionally, multinational companies are likely to be more encouraged to enter China’s NASH market as access and reimbursement in this region continue to improve, especially for diseases with high unmet need.
· How large is China’s drug-treatable NASH population, and how will the drug-treatment rate change during the forecast period?
· Which are the most commercially relevant drugs in China’s NASH market, and why? What are interviewed experts’ insights on current treatment options? Which clinical needs remain unfulfilled?
· What are the market access considerations for key therapies in the NASH pipeline in China? What sales / uptake could they secure in NASH? What are interviewed experts’ opinions of these therapies?
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 hepatologists and gastroenterologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalence of NASH by disease stage in urban versus rural China. Clinically and market-relevant drug-treatable populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key NASH therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase III: 1 drug; Phase II: 7 drugs; coverage of select Phase I products.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.